Corporate ProfileG1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer. G1’s two clinical assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of targets for anti-cancer therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as the backbone of multiple combination regimens. In addition, G1 is advancing G1T48, a potential first/best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates.
Stock Information

GTHX (Common Stock)


 0.41 (2.04%)


02/16/18 4:00 p.m. ET

Stock chart for: GTHX.O.  Currently trading at $19.69 with a 52 week high of $28.67 and a 52 week low of $12.04.
Recent NewsMore >>
02/14/18G1 Therapeutics to Report Fourth Quarter and Full-Year 2017 Financial Results on February 21, 2018Printer Friendly Version
01/02/18G1 Therapeutics to Present at 36th Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version
12/18/17G1 Therapeutics Added to Nasdaq Biotechnology IndexPrinter Friendly Version
12/06/17G1 Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Printer Friendly Version
Upcoming EventsMore >>
02/21/18 4:30 p.m. ET
Q1 2018 G1 Therapeutics, Inc. Earnings Conference Call
Data provided by Nasdaq. Minimum 15 minutes delayed.